VBY-825 is a member of a series of highly potent, spectrum-selective cathepsin inhibitors with structural diversity, which is being developed by Virobay. Increased cathepsin levels and activity have been shown to play a role in a variety of tumors, including lung and breast, and are correlated to poor patient prognosis. The proteolytic activity of multiple cathepsins may play a role in degradation of the basement membrane and extracellular matrix allowing a loss of cell adhesion and facilitating tumor metastasis. Cathepsin K inhibition has been shown to suppress bone resorption in women with post-menopausal osteoporosis as well as women with breast cancer by inhibiting osteoclast function. Studies with cathepsin S inhibitors have demonstrated a reduction in the perception of pain (nociception) in animals, with no sedating effects, suggesting a role for cathepsin S in neuropathic and inflammatory pain.
Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases that are key mediators in a variety of diseases, including autoimmunity, neuropathic pain, liver disease, cancer, and cardiovascular disorders. Virobay was founded upon a rich industry legacy of intensive research and development focused on the cathepsin family of cysteine proteases. Today, Virobay possesses a trove of maturing assets, including an advancing clinical pipeline and well-characterized libraries of highly potent and selective inhibitors with drug-like pharmacokinetics consistent with the potential for oral once-daily dosing in humans.
Virobay's unique expertise in the structure
|SOURCE Virobay, Inc.|
Copyright©2010 PR Newswire.
All rights reserved